Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03038477
Title A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Colorado, Denver
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.